Research graph
References from An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies
2014 · External reference
Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
10.1016/j.chom.2014.08.009 · 2014 · External reference
A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
10.1186/1743-422x-10-266 · 2013 · External reference
Current progress with serological assays for exotic emerging/re-emerging viruses
10.2217/fvl.13.60 · 2013 · External reference
Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation
10.1371/journal.pone.0076469 · 2013 · External reference
The use of equine influenza pseudotypes for serological screening
2012 · External reference
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes
10.3201/eid1103.040906 · 2005 · External reference
Pseudotype-based neutralization assays for influenza: a systematic analysis
10.3389/fimmu.2015.00161 · 2015 · External reference
Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors
10.1038/nprot.2009.22 · 2009 · External reference
The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes
2013 · External reference
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
10.1128/jvi.72.12.9873-9880.1998 · 1998 · External reference
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
10.1038/nbt0997-871 · 1997 · External reference
